Passage Bio 3Q 2026: EPS ($1.47) — 10-Q Summary
Passage Bio reported no revenue and a narrowed net loss of $4.72M for 3Q 2026, with EPS at ($1.47). The company wound down gene therapy programs, completed workforce restructuring, and expects to close a merger in 4Q 2026. Cash reserves were $20.2M, potentially insufficient for 12 months of operations.
How this was made

The 30-second read
Why it matters
The 10‑Q reveals a significant net‑loss reduction but still a negative EPS, with cash insufficient for a full year of operations, suggesting heightened downside risk unless the merger proceeds smoothly.
Market read
First disclosure of Passage Bio's quarterly performance and merger status; relevant for biotech micro‑caps and merger‑play traders.
What to watch
Potential hidden cash from asset sales or partnership opportunities not disclosed in the filing.
Background
Passage Bio is winding down its gene‑therapy programs and has approved a merger to address its cash constraints.
Ticker impact
Passage Bio filed its 10-Q showing no revenue, a narrowed net loss and a 75% workforce reduction, plus a pending merger.
likely pressure as investors price in weak earnings and limited cash
First report of the quarterly results with concrete loss figures and cash balance; micro‑cap stocks typically react sharply to such negative guidance.
Market effects
Highlights challenges in the gene‑therapy biotech sector and may pressure peer biotech stocks.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
The merger could unlock value if the combined entity secures funding, offering a turnaround play.
Key entities
- companyPassage Bio, Inc.
Biotech firm reporting its Q3 2026 results and merger approval.
